English | Español

Johnson & Johnson
Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission | Dec 20, 2019

JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer

Press release submission | Jun 14, 2019

JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis

Trending
+ Pharmaceuticals
Patient Daily | May 28, 2025

University of California medical researcher: ‘The 340B program is not associated with an improvement in mortality for low-income patients'
+ Pharmaceuticals
Patient Daily | May 29, 2025

Executive director of COA on 340B reform: ‘Start with PBMs then mega hospitals that pocket 340B discounts’
+ Pharmaceuticals
Patient Daily | May 27, 2025

New study shows effectiveness of recent RSV prevention strategies
+ Pharmaceuticals
Patient Daily | Jun 2, 2025

PathAI collaborates with Northwestern Medicine on digital pathology advancements